SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
For November 13, 2000 - January 3, 2001
NORTRAN PHARMACEUTICALS
-----------------------------------------------
(Translation of Registrant's name into English)
3650 Wesbrook Mall
-----------------------------------------------
(Address of principal executive offices)
Vancouver, British Columbia, V6S 2L2, CANADA
-----------------------------------------------
CIK # 0001036141 FILE NO. 0-29338
-----------------------------------------------
[Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or For 40-F]
Form 20-F [x] Form 40-F [ ]
[Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange act of
1934.]
Yes [x] No [ ]
<PAGE>
FORM 6-K
TABLE OF CONTENTS
For November 13, 2000 - January 3, 2001
NORTRAN PHARMACEUTICALS INC.
File No. 0-29338, CIK # 0001036141
Exhibit 1 Press Release - Dec. 15, 2000 (Cough Trial Results)
Exhibit 2 Material Change Form - December 14, 2000
<PAGE>
Exhibit 1
Nortran 3650 Wesbrook Mall Tel: 604-222-5577
Pharmaceuticals Inc. Vancouver, BC Fax: 604-222-6617
V6S 2L2 CANADA Website: www.nortran.com
--------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE TSE: NRT, CDNX: NRT, NASD BB: NTRDF
NORTRAN ANNOUNCES COUGH TRIAL RESULTS
-------------------------------------
Vancouver, Canada, December 15, 2000 - Nortran Pharmaceuticals Inc. (NRT-TSE)
announced today that its anti-cough drug CP1, did not show a statistically
significant inhibition of cough in its current Phase II clinical trial. The
phase II study assessed the ability of CP1 to reduce cough in patients suffering
from "idiopathic cough".
"Disappointing results are, unfortunately, a part of the drug discovery
business, and experienced at some time or another by every pharmaceutical
company," said Bob Rieder, President and CEO. "However, we remain confident
about Nortran and its future. Nortran is well financed. Our cardiology program
remains very strong with multiple clinical candidates identified, a partnership
in place, and an emerging discovery technology platform."
The blinded placebo-controlled cross-over phase II trial involved patients
selected for heightened sensitivity to cough stimuli, a condition called
idiopathic cough. The primary endpoint of the study was to determine whether
inhaled CP1 increased the amount of irritant required to induce cough in these
sensitive patients. The data showed that CP1 did not significantly increase the
amount of irritant required to induce cough.
"Intractable cough remains an important unmet medical need and our drug
candidate has a novel mechanism of action," Rieder continued. "We will look
closely at the data and the cough program over the next few weeks to decide what
our next steps should be."
Nortran Pharmaceuticals is a drug discovery company focused on cardiovascular
and respiratory applications of ion channel modulating drugs. In its program to
treat life-threatening cardiac arrhythmia, Nortran has developed several drug
candidates suitable for clinical testing as treatments for atrial arrhythmia.
Nortran has shown in preclinical studies that its drug candidates are both safe
and effective in the suppression of atrial arrhythmia, with little risk of the
dangerous side effects associated with current drugs. The company recently
achieved one of its most significant corporate milestones by signing the
licensing agreement with AstraZeneca PLC.
ON BEHALF OF THE BOARD
/s/ Bob Rieder
Robert Rieder
President & Chief Executive Officer
WARNING: THE COMPANY RELIES ON LITIGATION PROTECTION FOR "FORWARD-LOOKING"
STATEMENTS.
THE CANADIAN VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE
<PAGE>
Exhibit 2
ONTARIO
BRITISH COLUMBIA
ALBERTA
QUEBEC
FORM 27
SECURITIES ACT
MATERIAL CHANGE REPORT UNDER
SECTION 75(2) OF THE SECURITIES ACT (ONTARIO),
SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA),
SECTION 118(1) OF THE SECURITIES ACT (ALBERTA) AND
SECTION 73 OF THE SECURITIES ACT (QUEBEC)
Item 1. REPORTING ISSUER
Nortran Pharmaceuticals Inc.
3650 Wesbrook Mall
Vancouver, British Columbia V6S 2L2
Item 2. DATE OF MATERIAL CHANGE
December 14, 2000
Item 3. PRESS RELEASE
December 14, 2000 - Vancouver, British Columbia
Item 4. SUMMARY OF MATERIAL CHANGE
The Issuer's anti-cough drug CP1 did not show a statistically
significant inhibition of cough in its current phase II clinical
trial.
Item 5. FULL DESCRIPTION OF MATERIAL CHANGE
See press release dated December 14, 2000 for a full description.
Item 6. RELIANCE ON SECTION 75(3) OF THE SECURITIES ACT (ONTARIO) AND
EQUIVALENT SECTIONS OF OTHER JURISDICTIONS
Not Applicable.
Item 7. OMITTED INFORMATION
Not Applicable.
Item 8. SENIOR OFFICER
Name: Christina Yip
Title: Secretary
Phone No.: (604) 222-5577
<PAGE>
Item 9. STATEMENT OF SENIOR OFFICER
The foregoing accurately discloses the material change referred to
herein.
Dated at Vancouver, British Columbia, this 19th day of December, 2000.
NORTRAN PHARMACEUTICALS INC.
Per:
/s/ Christina Yip
------------------
Christina Yip
Secretary
IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE
FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT, AT THE TIME AND IN THE
LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
NORTRAN PHARMACEUTICALS INC.
----------------------------
(REGISTRANT)
Date: January 3, 2001
/s/ Christina Yip
----------------------------
Christina Yip
Secretary
<PAGE>
